Clinical Trial Update: Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of PRO 140 in HIV-uninfected male volunteers has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• PRO 140 (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2023-03-14